South State CORP. lifted its holdings in shares of AstraZeneca PLC (NYSE:AZN) by 6.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,466 shares of the company’s stock after buying an additional 5,021 shares during the period. South State CORP.’s holdings in AstraZeneca were worth $4,519,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Clear Harbor Asset Management LLC purchased a new stake in shares of AstraZeneca during the third quarter valued at $27,000. Simon Quick Advisors LLC purchased a new position in AstraZeneca in the third quarter worth about $30,000. Allworth Financial LP boosted its position in AstraZeneca by 500.0% in the second quarter. Allworth Financial LP now owns 600 shares of the company’s stock worth $32,000 after purchasing an additional 500 shares during the last quarter. TCTC Holdings LLC purchased a new position in AstraZeneca in the second quarter worth about $32,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in AstraZeneca in the third quarter worth about $46,000. 16.30% of the stock is currently owned by institutional investors.
Several research analysts have issued reports on the company. Berenberg Bank assumed coverage on AstraZeneca in a research report on Tuesday, September 29th. They issued a “buy” rating on the stock. Oddo Bhf raised AstraZeneca from a “reduce” rating to a “buy” rating in a research report on Wednesday, September 23rd. Zacks Investment Research cut AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 price objective on the stock. in a research report on Wednesday, July 29th. HSBC raised AstraZeneca from a “reduce” rating to a “hold” rating in a research report on Wednesday, November 11th. Finally, Barclays reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, July 29th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and an average price target of $61.00.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.03. The company had revenue of $6.58 billion during the quarter, compared to analysts’ expectations of $6.65 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. AstraZeneca’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.99 EPS. Equities analysts predict that AstraZeneca PLC will post 2.03 EPS for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases.
Featured Story: Market Perform
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.